LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

17.36 2.12

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.33

Max

17.55

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

77.256

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-5.88% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.33%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-10M

341M

Iepriekšējā atvēršanas cena

15.24

Iepriekšējā slēgšanas cena

17.36

Ziņu noskaņojums

By Acuity

50%

50%

165 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. nov. 23:51 UTC

Peļņas

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

2025. g. 5. nov. 23:10 UTC

Peļņas

DBS Third Quarter Net Dips 2.0%

2025. g. 5. nov. 22:55 UTC

Peļņas

Arm Holdings 2Q Profit Climbs on Record Demand

2025. g. 5. nov. 22:23 UTC

Peļņas

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

2025. g. 5. nov. 23:52 UTC

Peļņas

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

2025. g. 5. nov. 23:49 UTC

Peļņas

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

2025. g. 5. nov. 23:49 UTC

Peļņas

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

2025. g. 5. nov. 23:45 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

2025. g. 5. nov. 23:42 UTC

Tirgus saruna

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

2025. g. 5. nov. 23:12 UTC

Peļņas

Nutrien 3Q Adj EPS 97c >NTR.T

2025. g. 5. nov. 23:11 UTC

Peļņas

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

2025. g. 5. nov. 23:10 UTC

Peļņas

Nutrien 3Q Sales $6.01B >NTR.T

2025. g. 5. nov. 23:10 UTC

Tirgus saruna
Peļņas

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

2025. g. 5. nov. 23:10 UTC

Peļņas

Nutrien 3Q EPS 96c >NTR.T

2025. g. 5. nov. 23:04 UTC

Peļņas

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

2025. g. 5. nov. 23:03 UTC

Tirgus saruna

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

2025. g. 5. nov. 22:55 UTC

Tirgus saruna

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

2025. g. 5. nov. 22:55 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

2025. g. 5. nov. 22:51 UTC

Peļņas

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

2025. g. 5. nov. 22:50 UTC

Peļņas

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

2025. g. 5. nov. 22:44 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

2025. g. 5. nov. 22:43 UTC

Tirgus saruna
Peļņas

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

2025. g. 5. nov. 22:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 5. nov. 22:36 UTC

Tirgus saruna

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

2025. g. 5. nov. 22:20 UTC

Tirgus saruna

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

2025. g. 5. nov. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

2025. g. 5. nov. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

2025. g. 5. nov. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

Pfizer Responds to Delaware Chancery Court Ruling

2025. g. 5. nov. 22:01 UTC

Peļņas

Great-West Lifeco 3Q Net C$1.16B >GWO.T

2025. g. 5. nov. 22:01 UTC

Peļņas

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-5.88% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -5.88%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

165 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat